Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

This study has been completed.
Sponsor:
Collaborators:
University of Arizona
Providence Cancer Center, Earle A. Chiles Research Institute
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Cancer Research and Biostatistics Clinical Trials Consortium
ClinicalTrials.gov Identifier:
NCT01700400
First received: September 21, 2012
Last updated: November 21, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)